Seeking approval: Present and future therapies for pemphigus vulgaris

Current Opinion in Investigational Drugs

Volumn 9, Issue 5, 2008, Pages 497-504

  Mao, X ^a   Payne, A S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Autoantibody; Azathioprine; CD154; Cholinergic agonist; Cyclophosphamide; Dapsone; Intravenous immunoglobulin; p38 MAPK; Rituximab; TNF

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CD40 LIGAND; CHOLINERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAPSONE; DEXAMETHASONE; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PI 0824 VACCINE; PLACEBO; PREDNISOLONE; RITUXIMAB; VACCINE;

CLINICAL STUDY; CLINICAL TRIAL; COMPREHENSION; CYTOMEGALOVIRUS INFECTION; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATHOPHYSIOLOGY; PEMPHIGUS VULGARIS; PNEUMONIA; PYELONEPHRITIS; REVIEW; SEPTICEMIA;

ADRENAL CORTEX HORMONES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; AUTOANTIBODIES; CD40 LIGAND; CHOLINERGIC AGONISTS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEMPHIGUS; PLASMAPHERESIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43549117498     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Stanley JR: Pemphigus. In: Fitzpatrick's Dermatology in General Medicine. Edition 6, Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI (Eds), McGraw-Hill, New York, NY, USA (2003):558-567.
2. Ahmed AR, Yunis EJ, Khatri K, Wagner R, Notani G, Awdeh Z, Alper CA: Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci USA (1990) 87(19):7658-7662.
3. ClinicalTrials.gov: Pemphigus vulgaris. NIH, Bethesda, MD, USA (2008). http://www.clinicaltrials.gov/ct2/results?term=pemphigus+vulgaris
4. Sharma P, Mao X, Payne AS: Beyond steric hindrance: The role of adhesion signaling pathways in the pathogenesis of pemphigus. J Dermatol Sci (2007) 48(1):1-14. • This review highlights the signaling pathways for which chemical inhibitors have been reported to prevent in vitro and/or in vivo pathology caused by PV IgG.
5. Pfütze M, Niedermeier A, Hertl M, Eming R: Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol (2007) 17(1):4-11.
6. Murrell DF, Dick S, Amagai M, Barnadas MA, Borradori L, Bystryn J-C, Cianchini G, Diaz LA, Fivenson D, Goldsmith LA, Hall R et al: Consensus statement on definitions of disease endpoints and therapeutic response for pemphigus. J Am Acad Dermatol (2008): doi:10.1016/j.jaad.2008.01.012. • This document reports the consensus of international pemphigus experts on definitions of disease endpoints and therapeutic response, an important first step toward standardization of clinical trials in PV.
7. Enk AH, Knop J: Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet (1997) 350(9076):494.
8. Enk AH, Knop J: Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol (1999) 135(1):54-56.
9. Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC: Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol (2003) 139(6):739-742.
10. Beissert S, Werfel T, Frieling U, Böhm M, Sticherling M, Stadler R, Zillikens D, Rzany B, Hunzelmann N, Meurer M, Gollnick H et al: A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol (2006) 142(11):1447-1454. • This trial in patients with pemphigus (n = 40) investigated the relevant clinical question of the comparable safety and efficacy of azathioprine and MMF, which are widely considered to be first-line adjunctive immunosuppressants in PV.
11. NCT00140127: CellCept (mycophenolate mofetil) in pemphigus vulgaris. NIH, Bethesda, MD, USA (2005). http://www.clinicaltrials.gov/ ct2/show/NCT00140127?term=NCT00140127&rank=1
12. Aspreva Pharmaceuticals Corp: Aspreva and Roche receive orphan drug designation from FDA for evaluation of Cellcept in rare autoimmune disease pemphigus vulgaris. Press Release (2006): June 06.
13. CellCept prescribing information. Roche Pharmaceuticals, Nutley, NJ, USA (2007). http://www.rocheusa.com/products/cellcept/pi.pdf
14. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, Valikhani M, Balighi K, Hallaji Z, Barzegari M, Akhyani M, Ghodsi SZ, Seirafi H, Nazemi MJ et al: Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol (2007) 57(4):622-628. • This study was one of the largest clinical trials for PV in which patients (n = 120) were randomized to one of four relevant treatment regimens: prednisolone alone or prednisolone with azathioprine, MMF or pulse intravenous cyclophosphamide.
15. NCT00626678: Use of prednisone with placebo or azathioprine in pemphigus vulgaris. NIH, Bethesda, MD, USA (2008). http://www. clinicaltrials.gov/ct2/show/NCT00626678?term=azathiprine&rank=2
16. Reuther LO, Vainer B, Sonne J, Larsen N-E: Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders. The impact of TPMT genotyping in predicting toxicity. Eur J Clin Pharmacol (2004) 59(11):797- 801.
17. NCT00483119: Randomized trial of IVIg with or without cyclosporine in pemphigus. NIH, Bethesda, MD, USA (2007). http://www.clinicaltrials.gov/ ct2/show/NCT00483119?term=NCT00483119&rank=1
18. Olszewska M, Kolacinska-Strasz Z, Sulej J, Labecka H, Cwikla J, Natorska U, Blaszczyk M: Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol (2007) 8(2):85-92.
19. Cummins DL, Mimouni D, Anhalt GJ, Nousari CH: Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol (2003) 49(2):276-280.
20. Kanwar AJ, Kaur S, Thami GP: Long-term efficacy of dexamethasone-cyclophosphamide pulse therapy in pemphigus. Dermatology (2002) 204(3):228-231.
21. Hayag MV, Cohen JA, Kerdel FA: Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol (2000) 43(6):1065-1069.
22. Nousari CH, Brodsky R, Anhalt GJ: Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris. J Am Acad Dermatol (2003) 49(1):148-150.
23. Messer G, Sizmann N, Feucht H, Meurer M: High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris. Br J Dermatol (1995) 133(6):1014-1016.
24. Sami N, Qureshi A, Ruocco E, Ahmed AR: Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol (2002) 138(9):1158-1162.
25. Arredondo J, Chernyavsky AI, Karaouni A, Grando SA: Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in pemphigus. Am J Pathol (2005) 167(6):1531-1544.
26. Bystryn JC, Jiao D: IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity (2006) 39(7):601-607.
27. Li N, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz LA, Roopernian DC, Liu Z: Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest (2005) 115(12):3440-3450. • This study demonstrated that mice deficient for the neonatal Fc receptor are resistant to the protective effects of IVIg in mouse passive transfer models of autoimmune blistering disease, suggesting a potential mechanism for the clinical benefit of IVIg in autoantibody-mediated diseases.
28. Katz KA, Hivnor CM, Geist DE, Shapiro M, Ming ME, Werth VP: Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Arch Dermatol (2003) 139(8):991-993.
29. Heaphy MR, Albrecht J, Werth VP: Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol (2005) 141(6):699-702.
30. NCT00429533: Efficacy of dapsone as a steroid sparing agent in pemphigus vulgaris. NIH, Bethesda, MD, USA (2007). http://www. clinicaltrials.gov/ct2/show/NCT00429533?term=NCT00429533&rank=1
31. Werth VP, Fivenson D, Pandya AG, Chen D, Rico MJ, Albrecht J, Jacobus D: Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol (2008) 144(1):25-32.
32. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR: Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med (2006) 355(17):1772-1779. •• This trial combined the use of rituximab with IVIg in patients with PV (n = 11), of whom nine achieved clinical remission without adverse effects. The researchers suggested that IVIg serves to replace humoral immunity otherwise depleted by rituximab, thereby avoiding infectious complications.
33. Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B, Doutre MS et al: A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med (2007) 357(6):545-552. •• This trial demonstrated that a single cycle of rituximab is effective in patients with PV (n = 21), although two patients had serious infectious complications, including fatal septicemia.
34. Goh MS, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM: Rituximab in the adjuvant treatment of pemphigus vulgaris: A prospective open-label pilot study in five patients. Br J Dermatol (2007) 156(5):990-996.
35. Saito K, Nawata M, Iwata S, Tokunaga M, Tanaka Y: Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus. Rheumatology (2005) 44(11):1462-1464.
36. Sandborn WJ: Preventing antibodies to infliximab in patients with Crohn's disease: Optimize not immunize. Gastroenterology (2003) 124(4):1140-1145.
37. Grando SA, Glukhenky BT, Drannik GN, Epshtein EV, Kostromin AP, Korostash TA: Mediators of inflammation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid. Arch Dermatol (1989) 125(7):925-930.
38. Feliciani C, Toto P, Amerio P, Pour SM, Coscione G, Amerio P, Shivji G, Wang BH, Sauder DN: In vitro and in vivo expression of interleukin-1 α and tumor necrosis factor-α mRNA in pemphigus vulgaris: Interleukin-1 α and tumor necrosis factor-α are involved in acantholysis. J Invest Dermatol (2000) 114(1):71-77.
39. Pardo J, Mercader P, Mahiques L, Sanchez-Carazo JL, Oliver V, Fortea JM: Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol (2005) 153(1):222-223.
40. Jacobi A, Schuler G, Hertl M: Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-α inhibitor infliximab. Br J Dermatol (2005) 153(2):448-449.
41. Lin MH, Hsu CK, Lee JY: Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol (2005) 141(6):680-682.
42. NCT00135720: Study of etanercept (enbrel) in the treatment of pemphigus vulgaris. NIH, Bethesda, MD, USA (2007). http://www. clinicaltrials.gov/ct2/show/NCT00135720?term=NCT00135720&rank=1
43. NCT00283712: Use of infliximab for the treatment of pemphigus vulgaris. NIH, Bethesda, MD, USA (2008). http://www.clinicaltrials.gov/ ct2/show/NCT00283712?term=NCT00283712&rank=1
44. Wucherpfennig KW, Yu B, Bhol K, Monos DS, Argyris E, Karr RW, Ahmed AR, Strominger JL: Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: Charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci USA (1995) 92(25):11935-11939. • The researchers compared PV- and rheumatoid arthritis (RA)-linked alleles of HLA-DR4 and demonstrated that basic residues within a Dsg3 peptide confer specific binding to acidic residues in the peptide binding pocket of PV- but not RA-associated HLA haplotypes.
45. NCT00063752: Safety study of PI-0824 to treat pemphigus vulgaris. NIH, Bethesda, MD, USA (2005). http://www.clinicaltrials.gov/ct2/show/ NCT00063752?term=NCT00063752&rank=1
46. Anhalt G, Werth V, Strober B, Connolly M, Korman N, Greenstein D, Fantasia J, Kalish R: An open-label phase I clinical study to assess the safety of PI-0824 in patients with pemphigus vulgaris. J Invest Dermatol (2005) 125: Abs023.
47. Berkowitz P, Hu P, Liu Z, Diaz LA, Enghild JJ, Chua MP, Rubenstein DS: Desmosome signaling. Inhibition of p38MAPK prevents pemphigus vulgaris IgG-induced cytoskeleton reorganization. J Biol Chem (2005) 280(25):23778-23784.
48. Berkowitz P, Diaz LA, Hall RP, Rubenstein DS: Induction of p38MAPK and Hsp27 phosphorylation in pemphigus patient skin. J Invest Dermatol (2007) 128(3):738-740.
49. Berkowitz P, Hu P, Warren S, Liu Z, Diaz LA, Rubenstein DS: p38MAPK inhibition prevents disease in pemphigus vulgaris mice. Proc Natl Acad Sci USA (2006) 103(34):12855-12860. •• This study was the first to demonstrate that inhibition of the p38 MAPK pathway prevents PV in the murine passive transfer model, an in vivo follow up to an earlier study demonstrating that PV IgG causes activation of p38 MAPK in human keratinocytes.
50. Zhang J, Shen B, Lin A: Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol Sci (2007) 28(6):286-295. • Given the toxicities associated with first and second generation p38 MAPK inhibitors, this review examines other potential targets for inhibition within the p38 signaling pathway.
51. O'Neill LAJ: Targeting signal transduction as a strategy to treat inflammatory diseases. Nat Rev Drug Discov (2006) 5(7):549-563.
52. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM et al: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol (2005) 23(3):329-336.
53. NCT00606749: Use of KC706 for the treatment of pemphigus vulgaris. NIH, Bethesda, MD, USA (2008). http://www.clinicaltrials.gov/ct2/show/ NCT00606749?term=NCT00606749&rank=1
54. Liu Z, Li N, Diaz LA: Inhibition of pemphigus vulgaris by targeting of the CD40-CD154 co-stimulatory pathway: A step toward antigen-specific therapy? J Invest Dermatol (2006) 126(1):11-13.
55. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum (2003) 48(3):719-727.
56. Aoki-Ota M, Kinoshita M, Ota T, Tsunoda K, Iwasaki T, Tanaka S, Koyasu S, Nishikawa T, Amagai M: Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model. J Invest Dermatol (2006) 126(1):105-113. • This was the first demonstration that CD40/CD154 blockade prevents disease onset in an active immune mouse model of PV, although it did not ameliorate established disease in the same model.
57. Warren SJ, Lin MS, Giudice GJ, Hoffmann RG, Hans-Filho G, Aoki V, Rivitti EA, Santos V, Diaz LA: The prevalence of antibodies against desmoglein 1 in endemic pemphigus foliaceus in Brazil. Cooperative Group on Fogo Selvagem Research. N Engl J Med (2000) 343(1):23-30.
58. Mehta JN, Martin AG: A case of pemphigus vulgaris improved by cigarette smoking. Arch Dermatol (2000) 136(1):15-17.
59. Nguyen VT, Arredondo J, Chernyavsky AI, Pittelkow MR, Kitajima Y, Grando SA: Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. Arch Dermatol (2004) 140(3):327-334. • An intriguing study that offered in vivo and biochemical evidence that cholinergic agonists may ameliorate disease in PV, potentially through upregulation of classical cadherin-based cell adhesion.
60. Iraji F, Yoosefi A: Healing effect of pilocarpine gel 4% on skin lesions of pemphigus vulgaris. Int J Dermatol (2006) 45(6):743-746.
61. Chernyavsky AI, Arredondo J, Piser T, Karlsson E, Grando SA: Differential coupling of M1 muscarinic and α 7 nicotinic receptors to inhibition of pemphigus acantholysis. J Biol Chem (2008) 283(6):3401-3408.
62. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, Newcombe RG, Russell MA, Feyerabend C, Thomas GA, Sawe U: Transdermal nicotine for active ulcerative colitis. N Engl J Med (1994) 330(12):811- 815.
63. Amagai M, Tsunoda K, Suzuki H, Nishifuji K, Koyasu S, Nishikawa T: Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J Clin Invest (2000) 105(5):625-631.
64. Yeh SW, Cavacini LA, Bhol KC, Lin MS, Kumar M, Duval M, Posner MR, Ahmed AR: Pathogenic human monoclonal antibody against desmoglein 3. Clin Immunol (2006) 120(1):68-75.
65. Payne AS, Ishii K, Kacir S, Lin C, Li H, Hanakawa Y, Tsunoda K, Amagai M, Stanley JR, Siegel DL: Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. J Clin Invest (2005) 115(4):888-899.
66. Payne AS, Siegel DL, Stanley JR: Targeting pemphigus autoantibodies by their heavy chain variable region genes. J Invest Dermatol (2007) 127(7):1681-1691. • This study investigated restricted variable region gene usage by PV autoantibodies cloned by phage display and demonstrated that specific anti-idiotypic reagents can be used to adsorb or directly block disease-causing antibodies from the PV patient serum from whom the antibodies were cloned.
67. H gene segments in human Rh(D) red cell antibodies. Blood (1997) 89(9):3277-3286.
68. Szawlowski PW, Al-Safi SA, Dooley T, Maddocks JL: Azathioprine suppresses the mixed lymphocyte reaction of patients with Lesch-Nyhan syndrome. Br J Clin Pharmacol (1985) 20(5):489-491.
69. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis. Science (1995) 270(5234):286-290.
70. Nguyen VT, Arredondo J, Chernyavsky AI, Kitajima Y, Pittelkow M, Grando SA: Pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal effects on keratinocytes. J Biol Chem (2004) 279(3):2135-2146.
71. Brock N: The history of the oxazaphosphorine cytostatics. Cancer (1996) 78(3):542-547.
72. Wolf R, Tüzün B, Tüzün Y: Dapsone: Unapproved uses or indications. Clin Dermatol (2000) 18(1):37-53.